1-20 of 803 results for subject:"Medical treatments"
Librarians' tools
- Search time
- 0.315 seconds
- Solr query time
- 0.007 seconds
- Search query
- subject:"Medical treatments"
- We searched for
- subject_t:"Medical treatments" OR subject_ses:91973
Type
House
Session
Month
Department
More
Member
More
Primary member
More
Answering member
More
Legislative stage
Legislation
More
Subject
More
Publisher
To ask the Secretary of State for Health, with reference to the commercial agreement announced by NHS England on 9 November 2017, what the timetable is for NICE to issue final guidance on Perjeta (pertuzumab) in combination with Herceptin (trastuzumab) and docetaxel for HER2 positive metastatic or locally recurrent unresectable...
To ask the Secretary of State for Health, with reference to the commercial agreement announced by NHS England on 9 November 2017, what the timetable is for NICE to issue final guidance on Perjeta (pertuzumab) in combination with Herceptin (trastuzumab) and docetaxel for HER2 positive metastatic or locally recurrent unresectable...
The timetable for the National Institute for Health and Care Excellence’s (NICE) guidance on Perjeta (pertuzumab) in combination with Herceptin (trastuzumab) and docetaxel for HER2 positive metastatic or locally recurrent unresectable breast cancer is still to be confirmed. Perjeta remains available to new and existing National Health Service patients through the Cancer Drugs Fund pending NICE’s final guidance.
To ask the Secretary of State for Health, pursuant to the Answer of 17 October 2017 to Question 106474, when the NICE evaluation report through the Commissioning through Evaluation programme on Left Atrial Appendage Occlusion will be published.
To ask the Secretary of State for Health, pursuant to the Answer of 17 October 2017 to Question 106474, when the NICE evaluation report through the Commissioning through Evaluation programme on Left Atrial Appendage Occlusion will be published.
NHS England invested in a ‘commissioning through evaluation’ scheme which has provided additional data on the treatment’s cost and clinical effectiveness. NHS England advises that the scheme’s independent Evaluation Report - produced by the National Institute for Health and Care Excellence has been completed and an updated evidence review is being considered at NHS England’s national Clinical Panel in December.
If the evidence is supportive of a move to a routine commissioning position in the future, we will look to make a decision on a potential change to the national policy position on funding as soon as possible.
To ask the Secretary of State for Health, pursuant to the Answer of 17 October 2017 to Question 106474, when the review of the clinical commissioning policy for Left Atrial Appendage Occlusion will be completed.
To ask the Secretary of State for Health, pursuant to the Answer of 17 October 2017 to Question 106474, when the review of the clinical commissioning policy for Left Atrial Appendage Occlusion will be completed.
NHS England invested in a ‘commissioning through evaluation’ scheme which has provided additional data on the treatment’s cost and clinical effectiveness. NHS England advises that the scheme’s independent Evaluation Report - produced by the National Institute for Health and Care Excellence has been completed and an updated evidence review is being considered at NHS England’s national Clinical Panel in December.
If the evidence is supportive of a move to a routine commissioning position in the future, we will look to make a decision on a potential change to the national policy position on funding as soon as possible.
To ask the Secretary of State for Health, if he will assess the potential merits of establishing a national programme to provide fast-track treatment of Obstructive Sleep Apnoea for vocational drivers.
To ask the Secretary of State for Health, if he will assess the potential merits of establishing a national programme to provide fast-track treatment of Obstructive Sleep Apnoea for vocational drivers.
The Review of the Clinical Pathway for Sleep Apnoea is included on the National Institute for Health and Care Excellence’s priority lists and scoping will begin in the new year.
There are no plans of establishing a national programme to provide fast-track treatment of obstructive sleep apnoea for vocational drivers.
To ask the Secretary of State for Health, what information his Department holds on the average waiting time for children with mental health issues to receive treatment in Kirklees.
To ask the Secretary of State for Health, what information his Department holds on the average waiting time for children with mental health issues to receive treatment in Kirklees.
Information held on the average waiting time for children and young people being treated in National Health Service funded secondary mental health services is published in NHS England’s Five Year Forward View for Mental Health Dashboard tables. Information for quarter 1 2017/18 (April to June 2017), is available at:
To ask the Secretary of State for Health, how many clinical negligence claims relating to a stroke have been made against NHS trusts due to (a) a misdiagnosis and (b) mistreatment of atrial fibrillation in the last twelve months.
To ask the Secretary of State for Health, how many clinical negligence claims relating to a stroke have been made against NHS trusts due to (a) a misdiagnosis and (b) mistreatment of atrial fibrillation in the last twelve months.
NHS Resolution has supplied the following information:
NHS Resolution holds information relating to claims notified to it against pre-defined injury, cause and specialty codes. NHS Resolution has used the following search terms:
The total number of clinical claims where one of the injuries was ‘stroke’ and one of the causes was ‘Failure/Delay Diagnosis’ or ‘Wrong Diagnosis’, received 1 December 2016 to 30 November 2017 was 35.
NHS Resolution does not have a code for mistreatment of atrial fibrillation so it has undertaken a search of the number of clinical claims where one of the injuries was ‘stroke’ and ‘atrial fibrillation’ was mentioned in the incident details reported, received 1 December 2016 to 30 November 2017.
NHS Resolution has advised that it cannot provide the number of claims because to do so might lead to the identification of an individual.
To ask the Secretary of State for Health, whether his Department holds information on the longest period of time a child or young person has waited for mental health treatment in the NHS, in each of the last five years.
To ask the Secretary of State for Health, whether his Department holds information on the longest period of time a child or young person has waited for mental health treatment in the NHS, in each of the last five years.
The information requested is not held.
To ask the Secretary of State for Health, what assessment he has made of the effect of implementation of the recommendations of the Accelerated Access review on services to people with (a) Cystic Fibrosis and (b) other long-term conditions; and will he make a statement.
To ask the Secretary of State for Health, what assessment he has made of the effect of implementation of the recommendations of the Accelerated Access review on services to people with (a) Cystic Fibrosis and (b) other long-term conditions; and will he make a statement.
The Government and partners published the response to the Accelerated Access Review on 3 November which outlines plans for implementation. Since the Accelerated Access Collaborative has not yet selected any products, we have not made any assessment of the effect of implementation on any particular condition. The Accelerated Access Pathway will be operational from April 2018 when it will begin selecting products.
To ask the Secretary of State for Health, how many times Corneal Cross-Linking (CXL) treatment has been undertaken by the NHS in each of the last five financial years.
To ask the Secretary of State for Health, how many times Corneal Cross-Linking (CXL) treatment has been undertaken by the NHS in each of the last five financial years.
This information is not held centrally.
To ask the Secretary of State for Health, what assessment he has made of the potential effect of the use of (a) the drug Orkambi and (b) other new medicines for long-term conditions on (i) the budget of the NHS and (ii) resources available for hospital inpatients.
To ask the Secretary of State for Health, what assessment he has made of the potential effect of the use of (a) the drug Orkambi and (b) other new medicines for long-term conditions on (i) the budget of the NHS and (ii) resources available for hospital inpatients.
The National Institute for Health and Care Excellence (NICE) is the independent body that provides guidance on the prevention and treatment of ill health and the promotion of good health and social care. Through its technology appraisal programme, NICE provides authoritative, evidence-based guidance for the National Health Service on whether drugs and other treatments represent a clinically and cost effective use of resources. NHS organisations are legally required to make funding available for drugs and treatments recommended in NICE technology appraisal guidance.
NICE has recommended a number of drugs for the treatment of long-term conditions and has published resource impact tools alongside its recommendations to aid NHS organisations in assessing the expected impact of NICE’s recommendations. NICE published technology appraisal guidance in July 2016 that does not recommend Orkambi as a clinically and cost effective use of NHS resources
There has been a constructive dialogue between the company, NHS England and NICE, including discussion hosted through NICE’s confidential ‘Office for Market Access’, although NICE is yet to receive any fresh proposals from Vertex, the company that manufactures Orkambi. Both NHS England and NICE have been consistent in advice to Vertex, that progress can only be made by working through NICE’s appraisal processes and the existing commercial framework.
To ask the Secretary of State for Health, what assessment his Department has made of the potential benefits for people with long-term conditions such as cystic fibrosis of implementing the recommendations of the accelerated access review; and if he will make a statement.
To ask the Secretary of State for Health, what assessment his Department has made of the potential benefits for people with long-term conditions such as cystic fibrosis of implementing the recommendations of the accelerated access review; and if he will make a statement.
The Government and partners published the response to the Accelerated Access Review on 3 November which outlines plans for implementation. Since the Accelerated Access Collaborative has not yet selected any products, we have not made any assessment of the benefits for any particular condition. The Accelerated Access Pathway will be operational from April 2018 when it will begin selecting products.
To ask the Secretary of State for Health, what assessment his Department has made of the potential effect on patients with (a) rare and (b) ultra-rare diseases of NICE and NHS England’s proposals for changes to the arrangements for evaluating and funding drugs and other health technologies appraised through NICE’s...
To ask the Secretary of State for Health, what assessment his Department has made of the potential effect on patients with (a) rare and (b) ultra-rare diseases of NICE and NHS England’s proposals for changes to the arrangements for evaluating and funding drugs and other health technologies appraised through NICE’s...
We are committed to ensuring that patients with rare and ultra-rare diseases in England are able to access effective treatments.
The changes to the National Institute for Health and Care Excellence’s Highly Specialised Technologies methods are intended to introduce a fairer, more transparent framework for the evaluation of technologies for very rare diseases that will enable truly transformative new drugs for patients with rare diseases to be made available to patients where companies are willing to set prices that fairly reflect the added benefit they bring.
To ask the Secretary of State for Health, what discussions he has had with pharmaceutical companies on the provision of treatments for rare diseases.
To ask the Secretary of State for Health, what discussions he has had with pharmaceutical companies on the provision of treatments for rare diseases.
Departmental Ministers and officials regularly hold meetings and discussions with pharmaceutical companies to discuss a range of issues, including the availability of treatments for rare diseases.
To ask the Secretary of State for Health, what assessment he has made of the effect of the implementation of the recommendations from the Accelerated Access Review on people with cystic fibrosis; and what the timetable is for the implementation of those recommendations.
To ask the Secretary of State for Health, what assessment he has made of the effect of the implementation of the recommendations from the Accelerated Access Review on people with cystic fibrosis; and what the timetable is for the implementation of those recommendations.
The Government and partners published the response to the Accelerated Access Review on 3 November which outlines plans for implementation. Since the Accelerated Access Collaborative has not yet selected any products, we have not made any assessment of the effect of implementation on any particular condition. The Accelerated Access Pathway will be operational from April 2018 when it will begin selecting products.
To ask the Secretary of State for Health, what estimate his Department has made of the number of patients receiving treatment for arthritis in (a) South Tees NHS Trust, (b) the North East and (c) England.
To ask the Secretary of State for Health, what estimate his Department has made of the number of patients receiving treatment for arthritis in (a) South Tees NHS Trust, (b) the North East and (c) England.
No specific estimate has been made. The majority of patients receiving treatment for rheumatoid arthritis are managed in outpatient settings where data collection is not mandated.
What steps he is taking to support investment in life sciences for the development of new medical treatments.
What steps he is taking to support investment in life sciences for the development of new medical treatments.
The recently announced life sciences sector deal draws significant investment into the sector from across the world, ensuring that the next wave of breakthrough treatments, innovative medical research and technologies—and highly skilled jobs, of course—are created right here in Great Britain.
The recently announced life sciences sector deal draws significant investment into the sector from across the world, ensuring that the next wave of breakthrough treatments, innovative medical research and technologies—and highly skilled jobs, of course—are created right here in Great Britain.
The recently announced life sciences sector deal draws significant investment into the sector from across the world, ensuring that the next wave of breakthrough treatments, innovative medical research and technologies—and highly skilled jobs, of course—are created right here in Great Britain.
What steps he is taking to support investment in life sciences for the development of new medical treatments.
In Scotland today there are over 600 life sciences organisations employing more than 30,000 people, making Scotland one of the largest life sciences clusters in Europe, so they too will welcome the announcement the Minister mentions. Will he give the House some more detail on the sector deal and industry investments that could give even more strength to this world-leading industry across the United Kingdom?
In Scotland today there are over 600 life sciences organisations employing more than 30,000 people, making Scotland one of the largest life sciences clusters in Europe, so they too will welcome the announcement the Minister mentions. Will he give the House some more detail on the sector deal and industry investments that could give even more strength to this world-leading industry across the United Kingdom?
The sector’s commercial activity is very broadly spread across the whole of the UK—my hon. Friend’s concern. There are a number of strong emerging life sciences clusters. The deal highlights successes around the UK in Manchester, Leeds, Sheffield, Glasgow, south Wales, and the south-east, so it is a very broad spread.
The sector’s commercial activity is very broadly spread across the whole of the UK—my hon. Friend’s concern. There are a number of strong emerging life sciences clusters. The deal highlights successes around the UK in Manchester, Leeds, Sheffield, Glasgow, south Wales, and the south-east, so it is a very broad spread.
The sector’s commercial activity is very broadly spread across the whole of the UK—my hon. Friend’s concern. There are a number of strong emerging life sciences clusters. The deal highlights successes around the UK in Manchester, Leeds, Sheffield, Glasgow, south Wales, and the south-east, so it is a very broad spread.
In Scotland today there are over 600 life sciences organisations employing more than 30,000 people, making Scotland one of the largest life sciences clusters in Europe, so they too will welcome the announcement the Minister mentions. Will he give the House some more detail on the sector deal and industry investments that could give even more strength to this world-leading industry across the United Kingdom?